Body Dysmorphic Disorder Clinical Trial
Official title:
Efficacy of Cognitive Behaviour Therapy -v- Anxiety Management for Body Dysmorphic Disorder: a Randomised Controlled Trial
The aim of the research is to determine if Cognitive Behaviour Therapy (CBT) specific for BDD is more effective than a credible non-specific form of CBT for treating BDD and its delusional variant in adults aged 17 or over. This will be done in a single centre randomised controlled trial that compares specific CBT for BDD versus non-specific CBT over 12 weeks. The hypotheses to be tested are that: (1) specific CBT for BDD will be more effective than non-specific CBT at 12 weeks (2) Treatment effects from Specific CBT will be maintained at 1 month follow up. The main study end-point is at 12 weeks and the secondary end-point is at 1 month follow up. A secondary aim is to explore whether delusionality (insight) as measured by the Brown Assessment of Beliefs and co-morbid depressed mood predicts response to treatment.
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02635152 -
Interpretation Bias Modification for Body Dysmorphic Disorder
|
N/A | |
Completed |
NCT03673046 -
Waitlist-Control Trial of Smartphone Cognitive Behavioral Therapy (CBT) for Body Dysmorphic Disorder (BDD)
|
N/A | |
Recruiting |
NCT05402475 -
Online Cognitive Behavioural Therapy Intervention for Body Dysmorphic Disorder
|
N/A | |
Withdrawn |
NCT02843451 -
Milk Thistle in Body Dysmorphic Disorder
|
Phase 2 | |
Completed |
NCT02010619 -
Internet Delivered CBT for Body Dysmorphic Disorder
|
N/A | |
Completed |
NCT00842309 -
D-Cycloserine Augmentation of Behavior Therapy for Individuals With Body Dysmorphic Disorder
|
Early Phase 1 | |
Completed |
NCT00245635 -
Fluoxetine in Pediatric Body Dysmorphic Disorder
|
Phase 4 | |
Completed |
NCT02808702 -
Brain Correlates of Self-Focused Processing
|
N/A | |
Completed |
NCT01002326 -
Cognitive-Behavioral Therapy for Pediatric Body Dysmorphic Disorder
|
N/A | |
Active, not recruiting |
NCT01075672 -
Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals
|
N/A | |
Completed |
NCT02671266 -
Oxytocin Administration in BDD and OCD
|
Phase 2 | |
Completed |
NCT01038128 -
An Open Label Trial of Memantine in the Treatment of Bulimia Nervosa and Body Dysmorphic Disorder
|
N/A | |
Completed |
NCT01398865 -
Escitalopram Neuroimaging Supplement
|
N/A | |
Completed |
NCT00265109 -
Effectiveness of Levetiracetam in the Treatment of Body Dysmorphic Disorder
|
Phase 4 | |
Recruiting |
NCT04373629 -
Perceptual Abnormalities and Their Malleability in BDD
|
N/A | |
Completed |
NCT01453439 -
Cognitive-Behavioral Therapy and Supportive Psychotherapy for Body Dysmorphic Disorder
|
N/A | |
Completed |
NCT00106223 -
Treatment Study Investigating New Cognitive Behavioral Therapy Treatment Manual for Body Dysmorphic Disorder
|
N/A | |
Active, not recruiting |
NCT00211809 -
CBT as an Adjunct to SRIs in the Treatment of BDD
|
Phase 4 |